Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition
Executive Summary
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
You may also be interested in...
Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies
Private Company Edition: Alexis Borisy and his Curie.Bio co-founders will invest $5m-$7m to help companies get to lead optimization within 12-18 months. Also, Feng Zhang-founded Aera launched with $193m, Hexagon Bio raised a $77.3m series B round and Halda emerged with $76m.
Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track
Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.
Biotech Deals Stand Out In 2018 Korean Licensing Trends
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.